2,5-DMA

coronary artery disease, structural heart disease

2,5-DMA produces documented cardiovascular stimulation (tachycardia, blood pressure elevation) via sympathomimetic mechanisms. Pre-existing cardiovascular disease increases risk of acute cardiovascular events. Shulgin reported 'cardiovascular push' at 80 mg (PiHKAL #54).

2,5-DMA's sympathomimetic effects include blood pressure elevation. Individuals with pre-existing hypertension face compounded cardiovascular risk. No substance-specific data; inferred from DOx class and Shulgin's cardiovascular observations.

Sympathomimetic stimulation from 2,5-DMA may worsen pre-existing cardiac arrhythmias. The compound produces documented tachycardia at active doses. No substance-specific arrhythmia data exist.

epilepsy

Sympathomimetic agents can lower seizure threshold. Seizures have been reported with structurally related 25I-NBOMe (Hieger et al. 2015). No seizure data specific to 2,5-DMA exist.

No reproductive toxicity, teratogenicity, or lactation transfer data exist for 2,5-DMA. Contraindicated on precautionary grounds given the complete absence of safety data and known sympathomimetic cardiovascular activation.

Co-administration of MAOIs with 5-HT2A agonists carries risk of serotonin syndrome through elevated synaptic serotonin combined with receptor agonism. MAOIs may also potentiate 2,5-DMA effects by inhibiting CYP2D6-mediated O-demethylation. No substance-specific interaction data exist.

Combined use of SSRIs/SNRIs with 5-HT2A agonists may increase serotonin syndrome risk through additive serotonergic effects. The clinical significance for 2,5-DMA specifically is unknown given its weak 5-HT2A affinity (Ki ≈ 209 nM).

Tramadol combines SNRI activity with weak mu-opioid agonism. Co-administration with a 5-HT2A agonist could potentiate serotonergic toxicity. Listed as 'dangerous' in the existing DB interaction table. No published case report or preclinical study documents this specific combination with 2,5-DMA.